Article Dans Une Revue MMWR : Morbidity and Mortality Weekly Report Année : 2023

Notes from the Field : Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use — Six African Countries, 2021–2023

Mark. Deka
  • Fonction : Auteur

Résumé

Circulating vaccine-derived poliovirus (cVDPV) outbreaks can occur when oral poliovirus vaccine strains (most often, Sabin monovalent oral poliovirus vaccine type 2 [mOPV2]) undergo prolonged circulation in undervaccinated populations, resulting in genetic reversion to neurovirulence. A novel type 2 oral poliovirus vaccine (nOPV2) has been developed, which has been shown in clinical trials to be less likely than mOPV2 to revert to paralytic variants and to have limited genetic modifications in initial field use (1-4). Approximately 700 million doses of nOPV2 have been administered worldwide in response to outbreaks of cVDPV type 2 (cVDPV2). cVDPV2 detections originating from nOPV2 use from initial rollout during March 2021-September 7, 2023, are described in this report.

Fichier principal
Vignette du fichier
mm7238a4-H-2.pdf (401.76 Ko) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

pasteur-04255691 , version 1 (24-10-2023)

Licence

Identifiants

Citer

Jaume Jorba, Elizabeth Henderson, Mark. Deka, Kelley Bullard, Anfumbom Kfutwah, et al.. Notes from the Field : Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use — Six African Countries, 2021–2023. MMWR : Morbidity and Mortality Weekly Report, 2023, 72 (38), pp.1041-1042. ⟨10.15585/mmwr.mm7238a4⟩. ⟨pasteur-04255691⟩
155 Consultations
194 Téléchargements

Altmetric

Partager

  • More